金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived Accession #:P27038 N-terminal Sequence Analysis:Ala20 Structure:Disulfide-linked homodimer Purity:>95%, by SDS-PAGE under reducing conditions and visualized by silver stain. Predicted Molecular Mass:40.5 kDa (monomer) SDS-PAGE:60-65 kDa, reducing conditions Activity:Measured by its ability to inhibit Activin A-induced hemoglobin expression in K562 human chronic myelogenous leukemia cells. Schwall, R.H. etal. (1991) Method Enzymol. 198:340.The ED₅₀ for this effect is typically6 - 36 ng/mL in the presence of 3 ng/mL of recombinant human Activin A (Catalog # 338-AC). Formulation:Lyophilized from a 0.2 µm filtered solution in PBS.See Certificate of Analysis for details. Molecule Information: Activin RIIA Long Name: Activin Receptor IIA Aliases: ACVR2A; AVR2A Entrez Gene IDs: 92 (Human) Background: Activin Receptors Receptors for the TGF-beta superfamily comprise two groups, the type I and the type II serine/threonine kinases. These kinases are type I transmembrane proteins, and the two subgroups are distinguished by the presence of a glycine/serine-rich juxta-membrane domain found in the type I receptors. Either a type I or type II receptor may initially bind ligand, followed by recruitment of its alternate-type receptor counterpart to generate a heteromeric signaling complex. Type I receptors are referred to as the Activin Receptor-like Kinases (ALKs), while the type II receptors are named for the ligands they bind.